917974
BocA1V2PF2
同義詞:
(S)-2-((S)-1-((S)-2-((S)-2-((tert-Butoxycarbonyl)amino)propanamido)-2-cyclohexylacetyl)pyrrolidine-2-carboxamido)-3-(4-fluorophenyl)propanoic acid, IAP E3 ligase lead for protein degrader research, SNIPER building block
登入查看組織和合約定價
全部照片(1)
About This Item
經驗公式（希爾表示法）:
C30H43FN4O7
分子量：:
590.68
分類程式碼代碼:
41116105
NACRES:
NA.22
推薦產品
ligand
BocA1V2PF2
品質等級
形狀
powder
反應適用性
reagent type: ligand
官能基
carboxylic acid
儲存溫度
2-8°C
SMILES 字串
C[C@H](NC(OC(C)(C)C)=O)C(N[C@H](C(N1CCC[C@H]1C(N[C@H](C(O)=O)CC2=CC=C(C=C2)F)=O)=O)C3CCCCC3)=O
應用
BocA1V2PF2 is an in silico-derived inhibitor of apoptosis protein (IAP)-recruiting ligand for targeted protein degradation and SNIPER (specific and non-genetic IAP-dependent protein erasers) development, launched in partnership with ComInnex. Learn more about the novel IAP ligands generated through virtual screening of AVP mimetics in our Technology Spotlights. A C-terminal variant of BocA1V2PF2 is also available as A1V2PF2-NHEt (916714).
BocA1V2PF2 conjugates are also available for degrader synthesis. Browse our full synthesis offering here for streamlining
SNIPER and PROTAC® degrader libraries: Degrader Building Blocks
917443BocA1V2PF2-NHC6-NH2
917699 BocA1V2PF2-NHC10-NH2
917958 BocA1V2PF2-NHPEG1-NH2
916692 BocA1V2PF2-NHPEG3-NH2
BocA1V2PF2 conjugates are also available for degrader synthesis. Browse our full synthesis offering here for streamlining
SNIPER and PROTAC® degrader libraries: Degrader Building Blocks
917443BocA1V2PF2-NHC6-NH2
917699 BocA1V2PF2-NHC10-NH2
917958 BocA1V2PF2-NHPEG1-NH2
916692 BocA1V2PF2-NHPEG3-NH2
其他說明
法律資訊
PROTAC is a registered trademark of Arvinas Operations, Inc., and is used under license
相關產品
產品號碼
描述
訂價
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
分析證明 (COA)
輸入產品批次/批號來搜索 分析證明 (COA)。在產品’s標籤上找到批次和批號，寫有 ‘Lot’或‘Batch’.。
Tasuku Ishida et al.
SLAS discovery : advancing life sciences R & D, 26(4), 484-502 (2020-11-05)
Bifunctional degrader molecules, also called proteolysis-targeting chimeras (PROTACs), are a new modality of chemical tools and potential therapeutics to understand and treat human disease. A required PROTAC component is a ligand binding to an E3 ubiquitin ligase, which is then joined to another ligand binding to a protein to
Mikihiko Naito et al.
Drug discovery today. Technologies, 31, 35-42 (2019-06-16)
The induction of protein degradation by chimeric small molecules represented by proteolysis-targeting chimeras (PROTACs) is an emerging approach for novel drug development. We have developed a series of chimeric molecules termed specific and non-genetic inhibitor of apoptosis protein (IAP)-dependent protein
Nobumichi Ohoka et al.
The Journal of biological chemistry, 292(11), 4556-4570 (2017-02-06)
Many diseases, especially cancers, result from aberrant or overexpression of pathogenic proteins. Specific inhibitors against these proteins have shown remarkable therapeutic effects, but these are limited mainly to enzymes. An alternative approach that may have utility in drug development relies
我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.
聯絡技術服務